Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1413 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ORIGINAL ARTICLE Table of Contents   
Year : 2010  |  Volume : 21  |  Issue : 1  |  Page : 37-42
Management of chronic allograft dysfunction by switch over to rapamycin

1 Department of Nephrology, Pondicherry Institute of Medical Sciences, Pondicherry;Department of Nephrology, Madras Medical Mission Hospital, Chennai, India
2 Department of Nephrology, Madras Medical Mission Hospital, Chennai, India

Correspondence Address:
Georgi Abraham
Internal Medicine, Madras Medical Mission Hospital, J Jayalalitha Nagar, Chennai - 600037, Tamilnadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 20061690

Rights and PermissionsRights and Permissions

The aim of this study was to evaluate the efficacy of conversion from Calcineurin Inhibitors (CNI)-based to a rapamycin-based immunosuppressive regimen in renal transplant reci­pients who had allograft dysfunction, in a South Indian population. We analyzed the results of 75 (19.5%) of the 398 renal transplants performed over a five-year period from 2002 to 2007, who were converted from a CNI-based immunosuppression to rapamycin including patients with chronic allograft dysfunction, chronic allograft injury and malignancy. The data analyzed included serial rapamycin levels, serum creatinine, eGFR by nankivel formula, lipid profile, hemoglobin and serum potassium levels. Statistical analysis was performed using student's t test and the Kaplan Meir survival curve was used to predict probability of survival among patients on rapamycin. The mean age of the study patients was 39.6 ± 12.2 yrs and there was a male predominance (74.6%). Diabetic nephropathy was the predominant cause (36%) of end-stage renal disease (ESRD). Statistical analysis revealed a significant improvement in GFR of 14.6 mL/min and decrease in potassium by 0.7 mmol/L after initiation of rapamycin. There were no significant differences in terms of lipid profile, platelet count, hemoglobin and urine albumin levels. Rapamycin was discontinued in one patient due to hypokalemic nephropathy and in another patient due to delayed wound healing. To our knowledge, this is the first study to provide information on the conversion from a CNI to rapamycin-based immunosuppression in a cohort of Indian renal transplant recipients. In conclusion, the findings of our study confirm that rapamycin-based immunosuppressive regimen improves renal function and graft survival with mini­mal side effects, in comparison to CNI-based immunosuppression.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded581    
    Comments [Add]    
    Cited by others 3    

Recommend this journal